Carprazidil is oxadiazolopyrimidine derivative patented by pharmaceutical company Hoffmann-La Roche as a direct vasodilator and potent antihypertensive agent. In clinical trials, Carprazidil was evaluated in patients with moderate to severe arterial hypertension. Following the addition of Carprazidil to pre-existing therapy with diuretics and beta-blockers or sympatholytics, blood pressure in most of the patients was normalized within one month. Heart rate was only slightly increased. Orthostatic hypotension was not observed. Weight gain or oedema formation occurred in 14 patients within the first four weeks, but could be controlled satisfactorily by intensified diuretic therapy. After a mean duration of treatment of 2.8 months, plasma volume and plasma and urine sodium were unaltered, and plasma potassium was slightly decreased. Plasma renin activity was doubled, whereas plasma aldosterone concentrations were unaltered. No adverse side effects on hematological parameters, liver or renal function were observed, nor was antinuclear antibody detected.

Ditolamide is uricosuric drugs developed for the control of hyperuricemia in patients with gout.

Bumepidil (also known as CS-611) is intravenously administered coronary vasodilator with antiarrhythmic action. In anesthetized, open-chest dogs Bumepidil in doses of 0.1--1 mg/kg i.v. decreased systemic blood pressure, coronary resistance and arterio-venous oxygen difference and increased coronary sinus outflow in a dose-related manner, but myocardial oxygen consumption was virtually unchanged. At 0.3 mg/kg i.v. of the drug, coronary sinus outflow was doubled, but heart rate and AV conduction time were not changed. Bumepidil shortened the action potential duration (APD) of each tissue, especially of Purkinje fibers, without any significant alterations in the resting membrane potential, action potential amplitude and maximum rate of rising. Bumepidil can be characterized as a coronary dilator virtually devoid of cardiac actions in doses sufficiently increasing coronary blood flow.

Divaplon is one of a series of imidazopyrimidine derivatives, which are benzodiazepine receptor ligands. This compound exhibits anxiolytic and anticonvulsant activity but little or no sedative/myorelaxant effects. Divaplon occupied a large percentage of benzodiazepine receptors, as measured with an in vivo binding technique, without inducing any deficit in a rotating drum task in mice, and it is suggested that divaplon is a partial agonist at GABA receptors. No significant anticonvulsant tolerance was seen with the divaplon.

Niludipine (Bay-a-7168) is a potent calcium antagonistic coronary vasodilator with less cardiodepressant effect than nifedipine. Niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris. Niludipine is clinically useful as coronary vasodilator and hypotensive agent.

Octrizole (UV-329) is used as UV stabilizer within products to increase stability to light. It protects polymers as well as organic pigments from UV radiation helping to preserve the original appearance and physical integrity of polymeric systems; particularly in polyesters, polyvinyl chlorides, styrenics, acrylics, polycarbonates and polyvinyl butyral during outdoor weathering. Octrizole is an indirect additive used in food contact substances. It is used in cosmetics. The use levels of Octrizole (UV-329) range between 0.10 and 1.0%, depending on substrate and performance requirements of the final application. The product can be used alone or in combination with other additives such as light stabilizers (hindered amines), antioxidants (hindered phenols, phosphites, thiosynergists, hydroxylamines, benzofuranones), and other functional stabilizers and additives. The use of UV-329 in combination with hindered amine light stabilizers is particularly noteworthy in that a synergistic performance is often observed. Performance data of UV- 329 alone or in combination with other additives are available in selected substrates.

Demecycline is a tetracycline antibiotic drug. Tetracyclines have a broad spectrum of anti-microbial activity and act by interfering with bacterial protein synthesis. Demecycline is used to treat a wide range of infections caused by bacteria. Some of these infections are: Severe acne; Infections of the brain and liver caused by the bacteria Leptospira; Infection caused by Brucella bacteria (brucellosis); Infections caused by Rickettsiae micro-organisms transmitted by lice, fleas, ticks and mites; Infections of the sex organs and organs associated with urination (genito-urinary infections) such as an infection called chancroid, non-gonococcal urethritis; Rare infections such as Tularaemia and bubonic plague. The following undesirable effects have been reported for demecycline: loss of appetite, nausea, vomiting, diarrhea, inflammation of the tongue, difficulty in swallowing, intestinal inflammation, and inflammatory lesions, rashes, redness of the skin, pigmentation, sensitivity to light, acute kidney failure and others.

Cotriptyline is a tricyclic antidepressant, discovered by French Societe Industrielle pour la Fabrication des Antibiotiques. The compound antagonized reserpine-induced ptosis and bradycardia in rodents and potentiated stereotyped behavior induced by administration of d-amphetamine.